Heatwurx (NASDAQ:PCSA – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Heatwurx to post earnings of ($1.00) per share for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.
Heatwurx (NASDAQ:PCSA – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.19).
Heatwurx Price Performance
NASDAQ PCSA opened at $1.82 on Wednesday. The business has a fifty day simple moving average of $1.87 and a 200 day simple moving average of $2.39. Heatwurx has a 12 month low of $1.04 and a 12 month high of $10.84.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.
Check Out Our Latest Analysis on PCSA
About Heatwurx
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.
Featured Stories
- Five stocks we like better than Heatwurx
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.
-pt-telekomunikasi-indonesia-tbk-logo-1200x675.png){kind=logo}